For Healthcare Professionals
Propel treatment forward
For unresctable or metastatic liposarcoma or leiomyosarcoma after an anthracycline
YONDELIS® is the only treatment approved specifically for unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline-containing regimen1-3
Established in 6 open-label, single-arm trials, and 1 open-label, randomized, active-controlled clinical trial1
Find information about ordering YONDELIS® from specialty distributors
Considerations for treating unresectable or metastatic liposarcoma and leiomyosarcoma, 2 of the most common subtypes of soft tissue sarcoma4